Tamara Lea Doering

This study identifies therapeutic vulnerabilities in Cryptococcus neoformans using CRISPR-insert and machine learning, revealing new drug targets and synthetic lethal dependencies.

This paper identifies and characterizes two β-1,2-xylosyltransferases in Cryptococcus neoformans, showing they differentially impact glycan synthesis and capsule formation.

The paper maps the transcriptional regulatory network of Cryptococcus neoformans by analyzing TF deletions and identifies functionally orthologous TF pairs across species.

This study uses solid-state NMR to reveal five structural forms of α-glucans in Cryptococcus cell walls, showing their role in scaffolding and interacting with chitin, capsule, and melanin.

This study identifies Sac1 as a key factor in cryptococcal virulence by linking phosphoinositide turnover to host cell uptake and capsule production through genome-scale screening.

This paper identifies brilacidin as a novel antifungal agent effective against Cryptococcus neoformans, showing it reduces fungal survival in macrophages and potentiates existing antifungals.

The paper systematically analyzes how environmental signals affect capsule size and gene expression in C. neoformans using a large RNA-Seq dataset.